To collect a platform of 2D/3D cell cultures (organoids) of Soft Tissue Sarcomas.To collect a platform of Patient Derived Xenografts (PDX) of Soft Tissue Sarcomas of patients with (non-) metastatic sarcomas.To study the take rate of fresh PDX tumour…
ID
Source
Brief title
Condition
- Musculoskeletal and connective tissue neoplasms
- Miscellaneous and site unspecified neoplasms malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
To collect a platform of Patient Derived Xenografts (PDX) and 2D/3D cell
cultures of Soft Tissue Sarcomas.
Secondary outcome
not applicable
Background summary
Soft tissue sarcomas are rare and knowledge on the individual radiation
sensitivity is lacking. Performing prospective clinical studies into different
types of therapy in humans is hampered by the rarity of the disease.
Study objective
To collect a platform of 2D/3D cell cultures (organoids) of Soft Tissue
Sarcomas.
To collect a platform of Patient Derived Xenografts (PDX) of Soft Tissue
Sarcomas of patients with (non-) metastatic sarcomas.
To study the take rate of fresh PDX tumour material in nude mice.
To produce a consistent system for further anti-sarcoma therapy (both RT and
chemotherapy experiments)
To produce a model for translational research, for example systemic therapy
sensitivity assays.
To study the passage possibilities of 2D/3D cell cultures (organoids) by
freezing, storing and thawing.
To study the passage possibilities of PDX tumour material by freezing, storing,
thawing and re-inoculating in nude mice.
To study fractionation sensitivity on several STS subtypes in PDX.
Study design
the collection of fresh tumor material
Study burden and risks
one blood draw and, if necessary, one single extra tumor biopsy (4 needle
biopsies) under local anesthesia
Plesmanlaan 121
Amsterdam 1066CX
NL
Plesmanlaan 121
Amsterdam 1066CX
NL
Listed location countries
Age
Inclusion criteria
• Histologically confirmed (non-)metastatic intermediate to high grade STS
• Local recurrences are allowed
• Age >= 18 years
• Able and willing to undergo tumor biopsies or tumour sampling during surgery
• Localization of sarcoma enables safe biopsy or surgery
• Written informed consent
Exclusion criteria
• Known coagulation disorder and/or anticoagulant medication in as far it might interfere with a safe biopsy procedure (to the discretion of the treating physician and attending radiologist).
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the study.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| ClinicalTrials.gov | NCT02910895 |
| CCMO | NL58626.031.16 |